A glimpse into the pipeline for new therapies is always a highlight of our orphan drug report. For a quick read of the key takeaways, the team at Fierce Pharma has written this handy article. ow.ly/8rmG50RsAi1

#Pharma #RareDiseases

Not had time to read our brand new orphan drug report yet? Why not grab a few of the highlights, plus some excellent commentary in the #blog post from Daniel Chancellor?

📖 Read now: evaluate.com/blog/orphan-dr…

#OrphanDrugs #RareDiseases #Pharma #Biotech

Have you met Paul Verdin? He runs Evaluate Ltd's consulting practice and we recently caught up with him to talk about some of the interesting trends in the industry right now.

Click here to learn more about our consulting & analytics offering: evaluate.com/solutions/cons…

Evaluate’s latest #OrphanDrug #Report is out. Find out what's closing the gap between orphan and non-orphan drugs, who will top the charts by 2028, and how the IRA is shaking things up in the industry.

Download now: ow.ly/XbJV50Rnf0l

🧬Explore the present and future of #cell and #gene therapies in Evaluate's latest #report . 🧬 We look at how the market is growing, who the big players are, and what areas they're focusing on. Access the report here: evaluate.turtl.co/story/cell-and…

How did Q1 shape up for FDA approvals? In his latest article for Nature, Paul Verdin takes a look at a relatively quiet – but interesting - start to 2024. Subscription may be required. ow.ly/oywS50RjMcq

🧠 #Neurology is experiencing a resurgence. Here are some of the most interesting players. Who will come out top trumps with the next blockbuster?

Want to read the full #report ? Download it here: evaluate.com/thought-leader…

The Evaluate team is at Pharma CI Europe this week. Lots of great conversations already and yesterday, our own Alex Bour took to the stage to talk about how #CompetitiveIntelligence teams can drive success in #pharma . Come and find us to learn more!

Data and insight are critical to decision making in the #pharma market. In this new video, Daniel Chancellor talks about Evaluate Pharma and Norstella can deliver insight that helps reduce risk in your drug development strategy.

Don't miss the latest guest #blog from our partner Galen Growth, on essential reading for #DigitalHealth companies looking to establish themselves in the US and those who need to better understand the investment opportunities in digital health.

ow.ly/Rx3U50ReWv9

Evaluate and Inpart delved into the stages of finding that perfect partner. In our #webinar , we talked through those stages and highlighted the ways in which deep insight can help #pharma companies make smart decisions. Click below to read the #blog 👇

ow.ly/6waj50RaAwV

👋It’s Meet the Evaluate Pharma Team time again! 👋 In this edition, we chatted with Markella Kordoyanni from our #CompetitiveIntelligence #consulting practice to learn about what makes her tick. ow.ly/ryZR50R971N

Get your copy now for unbiased, data-driven insights, powered by HealthTech Alpha – the premier platform for Digital Health private market data, intelligence and insights. ow.ly/y6P850R7Ce4

Calling all #CompetitiveIntelligence teams in #pharma ! What do you need to know about the cell & gene therapy market? Our upcoming report will tell you, but for a sneak peek, check out the new #blog by Alex Bour, Ph.D. ow.ly/Bl9t50R46jg

🧠 Our latest #eBook analyses the #neurology landscape, looking at the resurgence of deals, recent breakthroughs in Alzheimer's research, the emergence of promising new molecules and mechanisms, and plenty more. Get the full analysis here: ow.ly/AWM550R2qvi

What will be the impact of #AI in #Pharma ? The team at PM360 spoke to our own Head of Data Science, Geoff Cunningham about R&D efficiencies and customised risk modelling. 👀 Take a look on page 44 of the latest edition: ow.ly/St7950QXyFc 👀

Antibody-drug conjugates (ADCs) are trumping all other drug classes in the #oncology market. Explore the ultimate #ADC showdown, featuring a deck of key players as well as rising biotechs with promising programmes.

Read the full report:evaluate.com/thought-leader…

Did 2023 see a shake up at the top of the pharma rankings? In his new #article for Nature Drug Discovery, Paul Verdin investigates the year-end data to find out. *Subscription may be required.
ow.ly/GOHK50QQkcJ

The #DigitalHealth ecosystem is undergoing a significant transformation. This new #blog by Julien de Salaberry, of Galen Growth, investigates 4 key themes behind this transformation. ow.ly/rqtc50QLKJw

Our #pharma experts are in the video hot seat today.

📽️Stay tuned for some new content where our consultants share their thoughts on some of the key trends and challenges facing #biotech and pharma companies. The blooper reel is disappointingly short at this stage!